StreetInsider.com News Articles

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

Tue, 19 May 2026 08:45:00 -0400

HIGHLIGHTS

New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study
Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer
Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study
Patient enrolment planned to begin by Q4 2026

Melbourne, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

Tue, 19 May 2026 08:45:00 -0400

HIGHLIGHTS

New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study
Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer
Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study
Patient enrolment planned to begin by Q4 2026

Melbourne, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

Tue, 19 May 2026 08:45:00 -0400

HIGHLIGHTS

New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study
Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer
Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study
Patient enrolment planned to begin by Q4 2026

Melbourne, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

Tue, 19 May 2026 08:45:00 -0400

HIGHLIGHTS

New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study
Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer
Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study
Patient enrolment planned to begin by Q4 2026

Melbourne, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

Tue, 19 May 2026 08:45:00 -0400

HIGHLIGHTS

New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study
Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer
Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study
Patient enrolment planned to begin by Q4 2026

Melbourne, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

Tue, 19 May 2026 08:45:00 -0400

HIGHLIGHTS

New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study
Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer
Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study
Patient enrolment planned to begin by Q4 2026

Melbourne, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b

OTC Markets Group Welcomes ATEX Resources Inc. to OTCQX

Tue, 12 May 2026 07:00:00 -0400

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ATEX Resources Inc. (TSX: ATX; OTCQX: ATXRF), a company focused on exploration and development of the Valeriano copper-gold-silver-molybdenum project in Chile, has qualified to trade on the OTCQX® Best Market. ATEX Resources Inc. upgraded to OTCQX from the OTCQB® Venture Market.